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ABSTRACT 
Pregnancy is a physiological hypercoagulable state, preparing the mother for the hemostatic challenge of 
delivery. However, this is associated with an increased risk of venous thrombosis and placenta-mediated 
complications, which present major challenges for mother and fetus. Although these conditions are 
heterogeneous in their pathophysiology, hereditary and acquired thrombophilia has been associated with 
recurrent pregnancy loss and gestational vascular complications, such as early-onset pre-eclampsia and 
placental abruption. Prevention of such placenta-mediated complications, which collectively complicate up 
to 15% of pregnancies, is a major issue for women’s health. Prospective interventional studies stratified by 
current knowledge of pathophysiological mechanisms related to placental and systemic hemostatic 
alterations will impact on the management of pregnancies at risk of these complications. 
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EPIDEMIOLOGY AND PATHOGENESIS OF 
PREGNANCY COMPLICATIONS 
Recurrent pregnancy loss and gestational vascular 
complications (GVC), including placental abruption, 
pre-eclampsia, and small-for-gestational age (SGA) 
pregnancies, are major gestational pathologies 
associated with detrimental maternal and fetal 
complications. These complications, affecting 5%–
15% of pregnant women, are attributed to decreased 
trophoblast invasion and chronic hypoxia due to 
uteroplacental underperfusion.1 The risk of recur-
rent pre-eclampsia is about 15% after one previous 
event, increasing to 30% after two consecutive 
pregnancies complicated by pre-eclampsia.2 
Impaired angiogenesis is reflected by the association 
between the clinical presentation of the disease and 
serum levels of soluble Flt-1 (fms-related tyrosine 
kinase 1) and placenta growth factor.3 Reduction in 
circulating levels of free soluble Flt-1 in women with 
pre-eclampsia could alleviate clinical signs of the 
syndrome.4,5 Placental abruption, defined as pre-
mature separation of a normally inserted placenta 
prior to delivery of the fetus, complicates 0.5%–1% 
of pregnancies and may lead to fetal death in some 
cases, particularly where the abruption involves 
more than 50% of the placenta.  
HEMOSTATIC CHANGES DURING 
NORMAL PREGNANCY AND GVC 
Pregnancy is a physiological hypercoagulable state 
characterized by a progressive increase in procoagu-
lant activity, which is maximal around term. In 
addition, there is a profound decrease in physiologic 
anticoagulants, including reduction in protein S 
activity and acquired activated protein C (APC) 
resistance.6,7 The overall fibrinolytic activity is 
impaired during pregnancy but returns rapidly to 
normal following delivery. Levels of prothrombin 
fragment 1+2, thrombin-antithrombin complexes, 
and D-dimer increase as pregnancy progresses.8 
These changes are considered to prepare the mother 
for the hemostatic challenge of delivery. 
Changes in the hemostatic system can lead to 
excessive uteroplacental thrombosis. Reduced pla-
cental perfusion due to failed vascular remodeling 
within the placental bed in early pregnancy is a 
hallmark of pre-eclampsia. Concentrations of tissue 
factor (TF) and free tissue factor pathway inhibitor 
(TFPI) are significantly increased in maternal 
plasma of pre-eclamptic women compared with 
normal pregnancy,9 while the TFPI-to-TF ratio is 
significantly lower in patients with pre-eclampsia 
than in normal pregnancy. The acquired changes in 
the physiological anticoagulant system are 
associated with increased thrombin generation and 
reduced birth-weight.10 Furthermore, higher 
maternal plasma concentrations of plasminogen 
activator inhibitor-1 (PAI-1) are observed in pre-
eclampsia compared to normal pregnancy.  
THROMBOPHILIA AND FETAL LOSS 
Acquired thrombophilia is associated with an 
increased risk of fetal loss, mainly in the first 
trimester, as observed in women with essential 
thrombocythemia. The obstetric definition of anti-
phospholipid syndrome (APLS) includes fetal loss at 
week 10 or later and recurrent consecutive 
embryonic losses (before week 10). It is currently 
thought that TF on maternal neutrophils is critical 
for the pathogenesis of APL-induced fetal loss, 
suggesting functional linkage between complement 
component C5a, TF, and neutrophil activation with 
subsequent decidual damage and fetal wastage.11  
Hereditary Thrombophilias  
It is well-established that thrombophilia increases 
the risk of thrombosis. Several reviews and meta-
analyses have attempted to assess the association 
between thrombophilic risk factors and gestational 
vascular complications.12,13 The major findings of the 
TREATS study, which systematically reviewed the 
area,13 point toward a modest increase in the relative 
risk, including a higher risk for a late pregnancy loss 
in the third trimester; stronger associations with 
recurrent pregnancy loss; and a higher risk of 
second trimester loss than of recurrent first 
trimester loss for factor V Leiden (FVL) and FII 
20210A heterozygotes. However, differences in 
design and conduct of the studies included in this 
systematic review and meta-analysis limited the 
conclusions. A meta-analysis of prospective cohort 
studies, providing a superior methodological design, 
demonstrated that the probability of pregnancy loss 
in FVL women was 52% higher, but this study had 
insufficient power to detect increased risks in 
women with FII 20210A polymorphism.14  
In the absence of clear and compelling evidence 
linking hereditary thrombophilias to pregnancy loss, 
and with no proven effective intervention, routine 
screening of pregnant women for hereditary throm-
bophilia is not recommended; however, screening of 
women with previous complications possibly associ-
ated with thrombophilia remains a matter of debate.  
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THROMBOPHILIA AND GESTATIONAL 
VASCULAR COMPLICATIONS 
The current data regarding the association of 
hereditary thrombophilia and GVCs are hetero-
geneous, and lack systematic integration of severity 
and co-factors. Nonetheless, these data demonstrate 
modest positive odds ratios for an association. 
Identifying a clear association opens up the possi-
bility of antithrombotic interventions, therefore 
screening of previously symptomatic women will 
depend on conclusive therapeutic developments in 
women harboring thrombophilia.  
While the global risk of placental abruption was 
found to be significant for a heterozygous FVL or a 
heterozygous FII 20210A polymorphism,13 this 
result was not reproduced in prospective studies.14 
An analysis of 22 publications showed an associa-
tion of placental abruption with FVL and FII 
20210A polymorphism.15 A recent prospective 
Canadian cohort study demonstrated that carriers of 
FVL or prothrombin gene mutation (PGM) are not 
at significantly increased risk of placenta-mediated 
complications.16 Thus, future collaborative efforts 
should focus on women with a history of severe 
pregnancy complications with clear definitions to 
create a more homogeneous study group.  
Placental Hemostasis 
Tissue factor is essential for embryogenesis, 
angiogenesis, invasion, and implantation. While TF 
is not presented on cells that are in contact with 
systemic circulation, the placental surface is in 
direct contact with maternal circulation, and tropho-
blast cells constitutively express high levels of 
TF.17,18 In addition, cytotrophoblast differentiation 
and fusion to syncytiotrophoblasts require initiation 
of apoptosis and exposure of negatively charged 
phospholipids on their membrane surface.19 The 
need for immediate inhibition of hemorrhage in the 
placental intervillous spaces during gestation, labor, 
and delivery explains the procoagulant nature of 
placental trophoblast and decidual cells.  
Tissue factor levels are regulated by a variety of 
physiological anticoagulants, including TFPI, endo-
thelial protein C receptor, thrombomodulin, and 
annexin V.  
Tissue factor pathway inhibitor is produced and 
pooled in the microvascular endothelial cells and in 
trophoblast cells18 and is highly expressed in pla-
cental tissues from the 10th week of pregnancy up to 
term.20 Low-molecular-weight heparins (LMWHs) 
stimulate expression, synthesis, and release of TFPI 
in endothelial cells and may exert their effect in 
pregnant women at risk for GVC, by modulating 
local hemostasis at the placental syncytiotrophoblast 
surface.20  
Microparticles in Normal Pregnancy and 
GVC 
Microparticles, shed from cell membranes upon 
activation or apoptosis, are involved in thrombosis, 
inflammation, and vascular dysfunction and may 
play an essential role in the maternal–placental 
cross-talk.21  
Microparticles obtained from healthy pregnant 
women demonstrate high procoagulant activity 
compared to non-pregnant females. The procoagu-
lant activity further increases in microparticles of 
women with GVC without a change in the TF expres-
sion, but with reduction in TFPI.22 A hemostatic 
balance, manifested by the TF/TFPI ratio on 
microparticles originating from maternal and 
placental cells, could reflect normal gestational 
hypercoagulability as well as the vascular injury 
characterizing GVC pathology.22 
Trophoblast differentiation yields substantial 
shedding of TF-bearing microparticles. Syncytio-
trophoblast microparticles circulating in maternal 
blood can lead to endothelial dysfunction, monocyte 
stimulation, and excessive maternal inflammatory 
reaction.23  
ANTICOAGULANT THERAPY DURING 
GESTATION 
A review of about 2,800 treated pregnancies, evalu-
ating safety and efficacy of LMWH in pregnancy, 
concluded that LMWH is the anticoagulant of choice 
during pregnancy.24  
Antithrombotics for Prevention of 
Pregnancy Loss 
The role of LMWH in the prevention of pregnancy 
complications remains uncertain. This possibility 
was stimulated by a single-center study25 that 
demonstrated, in women with thrombophilia and 
one previous pregnancy loss after 10 weeks of gesta-
tion, that the use of enoxaparin (40 mg daily) 
resulted in a significantly better live birth rate com-
pared to patients on low-dose aspirin (86% versus 
29%, respectively). The multicenter, prospective, 
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randomized LIVE-ENOX study compared two doses 
of enoxaparin in women with thrombophilia and a 
history of pregnancy loss and did not demonstrate a 
difference in live birth rates between the two 
dosages (84% for the 40 mg/d group and 78% for 
the 80 mg/d group).26 Another study comparing 
enoxaparin 40 mg/d to low-dose aspirin, reported a 
similar live birth rate in women with unexplained 
pregnancy loss in whom thrombophilia was ex-
cluded.27 Two recent prospective multicenter 
randomized trials, ALIFE and SPIN, reported that 
antithrombotic prophylaxis did not improve 
pregnancy outcome in women with at least two 
unexplained pregnancy losses.28,29 However, throm-
bophilia cases were a small minority in these trials, 
and the majority of cases of unexplained pregnancy 
loss could be attributed to other causes, including 
aneuploidy. Therefore, the women studied would 
have been heterogeneous in terms of the underlying 
cause of the loss such that antithrombotic treatment 
would have been unlikely to have been beneficial in 
the absence of a thrombotic mechanism for their 
loss. 
Antithrombotics for Prevention of 
Gestational Vascular Complications 
A Canadian randomized trial compared dalteparin 
5,000 units/d versus no prophylaxis in 110 women 
without identifiable thrombophilia who had prior 
placental-mediated complications.30  
Dalteparin was associated with a lower rate of 
composite primary outcome (severe pre-eclampsia, 
birth-weight less than the 5th percentile, major 
placental abruption( which occurred in 5.5% of 
those in the dalteparin arm compared to 23.6% in 
the no prophylaxis arm (OR 0.15, 95% CI 0.03–
0.70, P = 0.016). A single-center randomized study31 
in women with a prior placental abruption demon-
strated that prophylaxis with enoxaparin significant-
ly reduced the primary composite outcome (31.3% 
versus 12.5%). Subsequent studies will be required 
to confirm these findings.  
The recently published HAPPY trial, which had 
heterogeneous inclusion criteria,32 found no differ-
ence between intervention with LMWH (nadro-
parin) and the non-interventional arm for pregnan-
cy outcome. Potential limitations of this negative 
trial included under-representation of severe pre-
eclampsia, lack of information on the gestational age 
at the previous and present occurrence of pre-
eclampsia, and on the number of cases of pre-
eclampsia associated with fetal growth restriction/ 
small for gestational age (FGR/SGA).33  
The FRUIT study of women with heritable 
thrombophilia and early-onset pre-eclampsia 
demonstrated that adding LMWH to low-dose 
aspirin reduced recurrent pre-eclampsia onset 
before 34 weeks of gestation, but with no impact on 
general recurrence rates or overall outcome 
irrespective of gestational age.34 
A recent Cochrane review35 of 14 studies assessed 
treatment with heparin for women considered to be 
at particularly high risk of pregnancy complications 
secondary to placental insufficiency. This review 
found an association with a statistically significant 
reduction in risk of perinatal mortality (RR 0.40, 
95% CI 0.20–0.78), preterm birth before 34 (RR 
0.46, 95% CI 0.29–0.73) and 37 weeks of gestation 
(RR 0.72, 95% CI 0.58–0.90), and birth-weight 
below the 10th centile for gestational age (RR 0.41, 
95% CI 0.27–0.61), when compared with no 
treatment. A recent meta-analysis of LMWH for 
prevention of recurrent placenta-mediated preg-
nancy complications (PMPCs) performed in six 
randomized controlled studies which had included 
848 pregnant women with prior PMPCs concluded 
that LMWH may be a promising therapy for 
secondary prophylaxis, especially for severe or early 
pre-eclampsia (RR 0.16, 95% CI 0.07–0.36).36  
Recently, the TIPPS trial—a multicenter open-
label randomized study evaluating an antepartum 
prophylactic dose of dalteparin versus no dalteparin 
in women with increased-risk pregnancy and 
thrombophilia—showed no benefit for the interven-
tion arm.37 Of note, this study is characterized by a 
large variety of indications and a small number of 
patients at high risk due to previous severe placenta-
mediated complications, likely making the study 
population heterogeneous for the disease 
mechanism.  
FUTURE PERSPECTIVES 
Currently, we lack data on genome-wide association 
study (GWAS), biomarkers, and interventions 
applied to specific homogeneous populations. 
Defining and targeting specific disease processes 
amenable to antithrombotics and measuring the 
biological response as well as the clinical outcome 
will be valuable in advancing this field. Future 
studies should focus on examining antithrombotic 
interventions versus placebo (or suitable control) in 
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more homogeneous populations such as thrombo-
philic women with well-characterized severe preg-
nancy complications, or those stratified by patho-
logical findings, such as a severely infarcted placenta 
or validated biomarkers of the disease process. 
In summary, prevention of placenta-mediated 
complications remains a major health issue. 
Prospective interventional studies based on data on 
the pathophysiological mechanisms and systemic 
hemostatic alterations will pave the way for a better 
management of women and fetuses at risk. 
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